Smith & Nephew plc Upgraded by UBS AG to Buy (SNN)
Smith & Nephew plc (NYSE:SNN) was upgraded by equities researchers at UBS AG from a “neutral” rating to a “buy” rating in a research report issued on Monday, TheFlyOnTheWall.com reports.
Several other analysts have also recently commented on the stock. Analysts at Goldman Sachs Group Inc. downgraded shares of Smith & Nephew plc from a “neutral” rating to a “sell” rating in a research note to investors on Tuesday, January 21st. Separately, analysts at Bank of America Corp. upgraded shares of Smith & Nephew plc from a “neutral” rating to a “buy” rating in a research note to investors on Thursday, December 19th. Finally, analysts at Canaccord Genuity initiated coverage on shares of Smith & Nephew plc in a research note to investors on Monday, December 9th. They set a “buy” rating and a $77.00 price target on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Smith & Nephew plc currently has a consensus rating of “Hold” and an average price target of $77.00.
Shares of Smith & Nephew plc (NYSE:SNN) traded up 1.13% during mid-day trading on Monday, hitting $73.43. The stock had a trading volume of 70,983 shares. Smith & Nephew plc has a 1-year low of $52.52 and a 1-year high of $74.85. The stock has a 50-day moving average of $71.32 and a 200-day moving average of $64.66. The company has a market cap of $13.203 billion and a P/E ratio of 24.32.
Smith & Nephew plc is a global medical devices business operating in the orthopedics, endoscopy and advanced wound management markets.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.